181 related articles for article (PubMed ID: 37592269)
21. Challenging Salpingectomy as a Risk-Reducing Measure for Ovarian Cancer: Histopathological Analysis of the Tubo-Ovarian Interface in Women Undergoing Risk-Reducing Salpingo-oophorectomy.
Ayres C; Ratnayake G; McNally O; Quinn M
Int J Gynecol Cancer; 2017 May; 27(4):703-707. PubMed ID: 28399030
[TBL] [Abstract][Full Text] [Related]
22. Family history and BRCA1/BRCA2 status among Japanese ovarian cancer patients and occult cancer in a BRCA1 mutant case.
Hirasawa A; Masuda K; Akahane T; Ueki A; Yokota M; Tsuruta T; Nomura H; Kataoka F; Tominaga E; Banno K; Makita K; Susumu N; Sugano K; Kosaki K; Kameyama K; Aoki D
Jpn J Clin Oncol; 2014 Jan; 44(1):49-56. PubMed ID: 24218521
[TBL] [Abstract][Full Text] [Related]
23. [Significance and expression of PAX8, PAX2, p53 and RAS in ovary and fallopian tubes to origin of ovarian high grade serous carcinoma].
Mao YN; Zeng LX; Li YH; Liu YZ; Wu JY; Li L; Wang Q
Zhonghua Fu Chan Ke Za Zhi; 2017 Oct; 52(10):687-696. PubMed ID: 29060967
[No Abstract] [Full Text] [Related]
24. Peritoneal carcinoma in women with genetic susceptibility: implications for Jewish populations.
Casey MJ; Bewtra C
Fam Cancer; 2004; 3(3-4):265-81. PubMed ID: 15516851
[TBL] [Abstract][Full Text] [Related]
25. Risk-reducing salpingo-oophorectomy (RRSO) in BRCA mutation carriers: experience with a consecutive series of 111 patients using a standardized surgical-pathological protocol.
Powell CB; Chen LM; McLennan J; Crawford B; Zaloudek C; Rabban JT; Moore DH; Ziegler J
Int J Gynecol Cancer; 2011 Jul; 21(5):846-51. PubMed ID: 21670699
[TBL] [Abstract][Full Text] [Related]
26. Quantitative analysis of γ-H2AX and p53 nuclear expression levels in ovarian and fallopian tube epithelium from risk-reducing salpingo-oophorectomies in BRCA1 and BRCA2 mutation carriers.
Staff S; Tolonen T; Laasanen SL; Mecklin JP; Isola J; Mäenpää J
Int J Gynecol Pathol; 2014 May; 33(3):309-16. PubMed ID: 24681744
[TBL] [Abstract][Full Text] [Related]
27. Occult cancer of the fallopian tube in BRCA-1 germline mutation carriers at prophylactic oophorectomy: a case for recommending hysterectomy at surgical prophylaxis.
Paley PJ; Swisher EM; Garcia RL; Agoff SN; Greer BE; Peters KL; Goff BA
Gynecol Oncol; 2001 Feb; 80(2):176-80. PubMed ID: 11161856
[TBL] [Abstract][Full Text] [Related]
28. Incidental carcinomas in prophylactic specimens in BRCA1 and BRCA2 germ-line mutation carriers, with emphasis on fallopian tube lesions: report of 6 cases and review of the literature.
Carcangiu ML; Peissel B; Pasini B; Spatti G; Radice P; Manoukian S
Am J Surg Pathol; 2006 Oct; 30(10):1222-30. PubMed ID: 17001151
[TBL] [Abstract][Full Text] [Related]
29. Fallopian tube cancer- challenging to diagnose but not as infrequent as originally thought.
Hundal J; Lopetegui-Lia N; Rabitaille W
J Community Hosp Intern Med Perspect; 2021; 11(3):393-396. PubMed ID: 34234914
[No Abstract] [Full Text] [Related]
30. Validity of the 2014 FIGO Stage IIIA1 Subclassification for Ovarian, Fallopian Tube, and Peritoneal Cancers.
Matsuoka A; Tate S; Nishikimi K; Iwamoto M; Otsuka S; Shozu M
In Vivo; 2022; 36(5):2453-2460. PubMed ID: 36099140
[TBL] [Abstract][Full Text] [Related]
31. Serous carcinoma of the ovary, fallopian tube, or peritoneum presenting as lymphadenopathy.
Euscher ED; Silva EG; Deavers MT; Elishaev E; Gershenson DM; Malpica A
Am J Surg Pathol; 2004 Sep; 28(9):1217-23. PubMed ID: 15316322
[TBL] [Abstract][Full Text] [Related]
32. [The primary cancer of fallopian tube--a clinical case].
Ganovska A; Kovachev S
Akush Ginekol (Sofiia); 2015; 54(8):42-6. PubMed ID: 27032234
[TBL] [Abstract][Full Text] [Related]
33. Current management of fallopian tube carcinoma.
Gadducci A
Curr Opin Obstet Gynecol; 2002 Feb; 14(1):27-32. PubMed ID: 11801873
[TBL] [Abstract][Full Text] [Related]
34. Salpingo-oophorectomy and the risk of ovarian, fallopian tube, and peritoneal cancers in women with a BRCA1 or BRCA2 Mutation.
Finch A; Beiner M; Lubinski J; Lynch HT; Moller P; Rosen B; Murphy J; Ghadirian P; Friedman E; Foulkes WD; Kim-Sing C; Wagner T; Tung N; Couch F; Stoppa-Lyonnet D; Ainsworth P; Daly M; Pasini B; Gershoni-Baruch R; Eng C; Olopade OI; McLennan J; Karlan B; Weitzel J; Sun P; Narod SA;
JAMA; 2006 Jul; 296(2):185-92. PubMed ID: 16835424
[TBL] [Abstract][Full Text] [Related]
35. Pathological findings following risk-reducing salpingo-oophorectomy in BRCA mutation carriers: A systematic review and meta-analysis.
Cheng A; Li L; Wu M; Lang J
Eur J Surg Oncol; 2020 Jan; 46(1):139-147. PubMed ID: 31521389
[TBL] [Abstract][Full Text] [Related]
36. The lack of clinical value of peritoneal washing cytology in high risk patients undergoing risk-reducing salpingo-oophorectomy: a retrospective study and review.
Blok F; Roes EM; van Leenders GJ; van Beekhuizen HJ
BMC Cancer; 2016 Jan; 16():18. PubMed ID: 26768420
[TBL] [Abstract][Full Text] [Related]
37. Occult fallopian tube cancer in a patient with BRCA1 breast cancer.
Brown JV; Epstein HD; Mattison JN; Micha JP; Rettenmaier MA; Goldstein BH
J Minim Invasive Gynecol; 2008; 15(6):749-51. PubMed ID: 18971141
[TBL] [Abstract][Full Text] [Related]
38. Occult cancer of the fallopian tube in a BRCA2 germline mutation carrier at prophylactic salpingo-oophorectomy.
McEwen AR; McConnell DT; Kenwright DN; Gaskell DJ; Cherry A; Kidd AM
Gynecol Oncol; 2004 Mar; 92(3):992-4. PubMed ID: 14984974
[TBL] [Abstract][Full Text] [Related]
39. Cytomorphologic and molecular analyses of fallopian tube fimbrial brushings for diagnosis of serous tubal intraepithelial carcinoma.
Chui MH; Vang R; Wang TL; Shih IM; VandenBussche CJ
Cancer Cytopathol; 2019 Mar; 127(3):192-201. PubMed ID: 30861338
[TBL] [Abstract][Full Text] [Related]
40. [Oncopathological aspects of BRCA1 and BRCA2 genes inactivation in tumors of ovary, fallopian tube and pelvic peritoneum].
Škapa P; Dundr P
Cesk Patol; 2016; 52(4):199-204. PubMed ID: 27869446
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
